Gene therapy that induces the body to create microRNA-22, or miR-22, a naturally occurring molecule, successfully treated mice with hepatocellular carcinoma in a study at the UC Davis Comprehensive Cancer Center. The miR-22 treatment also reduced liver inflammation and produced better survival outcomes compared to the FDA-approved liver cancer treatment lenvatinib.
The Multiple Myeloma Research Foundation’s CoMMpass study, a prospective, longitudinal observational study of 1,143 newly diagnosed, previously untreated multiple myeloma patients, revealed critical genetic markers that can better predict disease progression and identify patients at risk of transitioning to more aggressive forms of the disease.
